Hinge Health, Inc. (HNGE) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Hinge Health, Inc. is a digital health company providing AI-powered musculoskeletal (MSK) care solutions to self-insured employers, health plans, and government entities. The company completed its Initial Public Offering (IPO) in May 2025, raising approximately $255.7 million in net proceeds, which were primarily used to pay employee taxes on stock settlements. The company operates as an "emerging growth company" and maintains a dual-class stock structure.
Key Financial Metrics
| Metric (in thousands, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $587,860 | $390,404 | +51% |
| Gross Profit | $468,222 | $299,902 | +56% |
| Gross Margin | 80% | 77% | +300 bps |
| Operating Loss | $(546,371) | $(31,910) | Widened significantly |
| Net Loss | $(528,261) | $(11,933) | Widened significantly |
| Free Cash Flow | $179,604 | $45,229 | +297% |
| Cash & Marketable Securities | $477,000 | $466,572 | As of Dec 31, 2025 |
Note: The 2025 Net Loss includes approximately $643 million in stock-based compensation (SBC) expense, primarily due to the satisfaction of liquidity-based vesting conditions triggered by the May 2025 IPO.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 51% year-over-year, driven by expansion within existing client bases and new client additions. The company grew its client base to 2,830 (from 2,256 in 2024) and contracted lives to approximately 25 million.
- Expense Surge: Operating expenses increased dramatically, totaling $1.01 billion in 2025 compared to $332 million in 2024. This was largely due to non-cash SBC expenses ($643 million total) and increased investments in R&D and Sales & Marketing.
- Non-GAAP Performance: On a non-GAAP basis (excluding SBC and other non-recurring items), the company reported an operating income of $119.5 million (20% margin) in 2025, compared to a non-GAAP operating loss of $26.1 million in 2024.
- Share Repurchases: The company initiated a $250 million share repurchase program in November 2025 and repurchased approximately $65 million worth of shares by year-end.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects continued growth through expanding its client base, increasing adoption within existing clients, and international expansion (currently active in Canada, France, Germany, Ireland, Netherlands, and UK). The company is transitioning to an engagement-based pricing model for some clients and launched "HingeSelect," an in-person provider network, in 2025.
Key Risks:
- Profitability: The company has a history of net losses and anticipates increasing expenses. While non-GAAP metrics show profitability, GAAP losses remain significant due to SBC.
- Partner Concentration: A substantial portion of revenue (82% in 2025) is derived through a limited number of health plan partners. The top three partners accounted for over 40% of revenue.
- Regulatory Environment: The business is subject to evolving regulations regarding telehealth, AI in healthcare, and medical devices (specifically the Enso device). Changes in laws could increase compliance costs or restrict operations.
- AI Reliance: Increasing reliance on AI technologies introduces risks related to data accuracy, regulatory scrutiny, and potential third-party claims.
Investor Verification Checklist
- SBC Impact: Verify the sustainability of operating margins by analyzing the trajectory of stock-based compensation post-IPO, as the 2025 GAAP loss is heavily skewed by one-time vesting events.
- Partner Dependency: Review the renewal terms and concentration risk associated with the top three health plan partners (HCSC, Elevance, Aetna), which collectively drive a significant portion of revenue.
- Engagement Metrics: Monitor "LTM Average Eligible Lives" and member engagement rates to validate the effectiveness of the new engagement-based pricing models.
- Regulatory Status: Confirm the status of FDA clearances for the Enso device and any new regulatory requirements for the AI-powered TrueMotion technology.
- Cash Burn vs. Generation: Assess the company's ability to maintain positive free cash flow as it scales international operations and invests in the HingeSelect network.